** Medical device maker ResMed's RMD.N shares rise 8.1% to $231.81
** RMD posted late on Wednesday Q1 adj. profit of $2.37 per share, beating analysts' estimates of $2.36 per share, according to data compiled by LSEG
** Company's Q1 revenue rose 8% to $1.29 billion
** ResMed said it is "very well positioned" and does not expect the introduction of U.S. tariffs to have a material impact on its financial results
** Brokerage William Blair says ResMed products are also exempt from the announced April tariffs, making it "one of the safer stories, if not the safest, from recent headlines"
** "We are decreasing our forward EPS estimates modestly, given a challenging macro environment" - Jefferies
** As of last close, RMD has risen 1.3% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。